Insulin therapy is the only option for type 1 diabetes (T1D) patients. Yet, this therapy is suboptimal. Central problem remains to achieve a proper glycemic control without the risk of life- threatening hypoglycemia and ketoacidosis. Diatheris is a spinoff from University of Geneva with the goal of developing a new therapeutic solution to overcome these limitations and improve T1D management. Diatheriss lead program consists in developing a proprietary game-changing approach based on a small protein called S100A9. S100A9 treatment is exploiting an insulin-independent pathway, which has shown remarkable results in combination with low-dose insulin, to improve glycemic control (normalizing glycemia) without the risk of hypoglycemia and ketoacidosis.